John E Pimanda
Overview
Explore the profile of John E Pimanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
3631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Truong P, Shen S, Joshi S, Islam M, Zhong L, Raftery M, et al.
Nat Commun
. 2024 Aug;
15(1):7360.
PMID: 39198401
Hypomethylating agents (HMAs) are frontline therapies for Myelodysplastic Neoplasms (MDS) and Acute Myeloid Leukemia (AML). However, acquired resistance and treatment failure are commonplace. To address this, we perform a genome-wide...
3.
Thoms J, Koch F, Raei A, Subramanian S, Wong J, Vafaee F, et al.
Nucleic Acids Res
. 2023 Oct;
52(D1):D1131-D1137.
PMID: 37870453
The BloodChIP Xtra database (http://bloodchipXtra.vafaeelab.com/) facilitates genome-wide exploration and visualization of transcription factor (TF) occupancy and chromatin configuration in rare primary human hematopoietic stem (HSC-MPP) and progenitor (CMP, GMP, MEP)...
4.
Subramanian S, Thoms J, Huang Y, Cornejo-Paramo P, Koch F, Jacquelin S, et al.
Blood
. 2023 Aug;
142(17):1448-1462.
PMID: 37595278
Hematopoietic stem and progenitor cells (HSPCs) rely on a complex interplay among transcription factors (TFs) to regulate differentiation into mature blood cells. A heptad of TFs (FLI1, ERG, GATA2, RUNX1,...
5.
Moles E, Howard C, Huda P, Karsa M, McCalmont H, Kimpton K, et al.
Sci Transl Med
. 2023 May;
15(696):eabm1262.
PMID: 37196067
High-risk childhood leukemia has a poor prognosis because of treatment failure and toxic side effects of therapy. Drug encapsulation into liposomal nanocarriers has shown clinical success at improving biodistribution and...
6.
7.
Schnegg-Kaufmann A, Thoms J, Sarower Bhuyan G, Hampton H, Vaughan L, Rutherford K, et al.
Blood
. 2022 Dec;
141(11):1316-1321.
PMID: 36493342
Myelodysplastic neoplasms (MDSs) and chronic myelomonocytic leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMAs) can modify the clinical course...
8.
Mesoderm-derived PDGFRA cells regulate the emergence of hematopoietic stem cells in the dorsal aorta
Chandrakanthan V, Rorimpandey P, Zanini F, Chacon D, Olivier J, Joshi S, et al.
Nat Cell Biol
. 2022 Jul;
24(8):1211-1225.
PMID: 35902769
Mouse haematopoietic stem cells (HSCs) first emerge at embryonic day 10.5 (E10.5), on the ventral surface of the dorsal aorta, by endothelial-to-haematopoietic transition. We investigated whether mesenchymal stem cells, which...
9.
Kapeni C, Nitsche L, Kilpatrick A, Wilson N, Xia K, Mirshekar-Syahkal B, et al.
Blood
. 2022 Jun;
140(5):464-477.
PMID: 35653588
Hematopoietic stem cells (HSCs) are of major clinical importance, and finding methods for their in vitro generation is a prime research focus. We show here that the cell cycle inhibitor...
10.
Liu Y, Kwon J, Fabiani E, Xiao Z, Liu Y, Follo M, et al.
N Engl J Med
. 2022 May;
386(21):1998-2010.
PMID: 35613022
Background: Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated. Methods: We examined the effect of...